Table 4. 3-year overall and progression-free survival in 28 patients after radioembolization for intrahepatic cholangiocarcinoma.
Parameter | Overall survival (%) in Months | Progression-Free survival (%) in Months | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
6 | 12 | 18 | 24 | 30 | p-value | 6 | 12 | 18 | 24 | 30 | p-value | |
All Patients | 96 | 78 | 67 | 59 | 59 | 74 | 45 | 40 | 25 | 25 | ||
Anatomic Distribution | 0.403 | 0.003 | ||||||||||
Segmental (n = 9) | 88 | 88 | 88 | 59 | 59 | 88 | 88 | 88 | 59 | 59 | ||
Unilobar (n = 8) | 100 | 83 | 83 | 83 | 83 | 878 | 39 | 39 | 39 | 39 | ||
Bilobar (n = 11) | 100 | 68 | 43 | 43 | 43 | 55 | 18 | 9 | 0 | 0 | ||
Tumor Focality | 0.112 | 0.002 | ||||||||||
Solitary (n = 16) | 93 | 85 | 85 | 85 | 85 | 87 | 63 | 63 | 63 | 63 | ||
Multifocal (n = 12) | 100 | 71 | 49 | 37 | 37 | 58 | 25 | 17 | 0 | 0 | ||
Tumor Morphology | 0.002 | 0.382 | ||||||||||
Mass Forming (n = 22) | 95 | 90 | 77 | 68 | 68 | 67 | 52 | 46 | 29 | 29 | ||
Periductal/intraductal (n = 6) | 100 | 0 | 0 | 0 | 0 | 100 | 11 | 0 | 0 | 0 |